4SC announces update relating to Resminostat’s (Kinselby) Marketing Authorisation Application
Planegg-Martinsried, Germany, 7 January 2025 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage cutaneous T-cell lymphoma (CTCL), today announced that it had submitted its responses to the Day-120 List of Questions from the European Medicines Agency (EMA) in December 2024 as planned, following 4SC’s initial Marketing Authorisation Application (MAA) filing for resminostat (Kinselby) in March 2024. The EMA has notified 4SC that examination of the Company’s MAA shall continue according to schedule.
